O ral anticoagulation with the vitamin K antagonist warfarin reduces the rate of thromboembolic events for patients in a variety of clinical settings. 1 However, warfarin therapy is challenging because there is wide variation among patients in response and therefore in dose requirement. To achieve and maintain an optimal warfarin dose, the prothrombin time and the international normalized ratio (INR) are monitored, and doses are adjusted to maintain each patient's INR within a narrow therapeutic range. An INR of less than 2 is associated with an increased risk of thromboembolism, 2 and an INR of 4 or more is associated with an increased risk of bleeding. 3 Polymorphisms in the gene encoding the cytochrome P-450 2C9 enzyme (CYP2C9) are known to contribute to variability in sensitivity to warfarin. CYP2C9 is the enzyme primarily responsible for the metabolic clearance of the S-enantiomer of warfarin. 4, 5 Patients with certain common genetic variants of CYP2C9 require a lower dose of warfarin and a longer time to reach a stable dose. They are also at higher risk for over-anticoagulation and serious bleeding. 6, 7 Vitamin K epoxide reductase (VKORC1) recycles vitamin K epoxide to the reduced form of vitamin K, an essential cofactor in the formation of the active clotting factors II, VII, IX, and X through γ-glutamyl carboxylation. 8 VKORC1 is the target of coumarin anticoagulants, and its common genetic variants result in altered sensitivity to warfarin. VKORC1 polymorphisms are associated with a need for lower doses of warfarin during longterm therapy [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and, in some studies, were found to contribute to the variation in dose requirement more than CYP2C9 variants.
On the basis of these observations, the Food and Drug Administration (FDA) approved a labeling change for warfarin that describes the reported effects of VKORC1 and CYP2C9 on dose requirements. 20 The package insert as of August 2007 states that "lower initiation doses should be considered for patients with certain genetic variations in CYP2C9 and VKORC1 enzymes." The FDA also approved clinical tests for these genetic variants. 21 However, there is little information about the relative contributions of VKORC1 and CYP2C9 to the anticoagulation response in patients during the initiation of warfarin therapy. The first months of anticoagulant treatment are particularly problematic, since the safe and effective dose for an individual patient is not known and is determined empirically. Consequently, the risk of over-anticoagulation, with the potential for hemorrhagic complications, is higher during this time than subsequently. 3, 22, 23 Therefore, genotyping in order to individualize the warfarin dose is likely to have the greatest effect during the initiation of treatment. Thus, we evaluated the effect of variant CYP2C9 and VKORC1 alleles in a cohort of patients that had been assembled prospectively to evaluate genetic contributions to the early phase of anticoagulation.
Me thods

Study Design and Eligibility
The study was conducted at three anticoagulation clinics affiliated with the Vanderbilt University Medical Center: the Pharmacy, Cardiology, and Arthritis and Joint Replacement Center clinics. Patients presenting for initiation of warfarin therapy were prospectively screened to determine eligibility for the study and were enrolled if they provided written informed consent. The center's institutional review board approved the study.
To be eligible, patients at least 18 years of age needed to have started warfarin therapy between July 2002 and July 2004. Exclusion criteria were a diagnosis of active cancer requiring, or with the potential to require, concurrent chemotherapy, as well as active alcoholism.
The target therapeutic INR range was determined by each patient's physician and varied according to the indication for warfarin treatment. Concurrent medications were categorized into groups of drugs that might potentiate or attenuate the anticoagulant effect of warfarin. 1,24 Amiodarone, because of its marked effects, 25 was considered separately.
Data Collection and Follow-up
A trained nurse collected study data by interviewing patients, reviewing their medical records, and obtaining a venous blood sample for DNA extraction. Recorded at baseline were the patient's age, sex, racial or ethnic background, indication for warfarin therapy, date of initiation of warfarin, target INR range, initial warfarin dose, and concomitant medications. Data regarding subsequent INR values and warfarin doses, the fre-quency of INR monitoring, and bleeding events were obtained from medical records. Information was recorded in an Oracle database. All patients were followed from the first date of warfarin use until the end of follow-up or the end of treatment at Vanderbilt University Medical Center; the latter was defined as the absence of an INR measurement in the medical record for more than 60 days. The closing date for data collection was July 12, 2004.
Genotyping
CYP2C9 genotyping was performed with the use of a fluorescent allele-specific oligonucleotide ligation assay after initial polymerase-chain-reaction amplification with the use of primers for the major variant alleles CYP2C9*2 (430C→T; rs1799853), 26 CYP2C9*3 (1075A→C; rs1057910), and CYP2C9*5 (1080C→G; rs28371686), as described previously. 27 (See Table 1 Table 2 of the Supplementary Appendix) or TaqMan Validated SNP assays (C_2847860_10 and C_26291751_ 10) with the 7900HT Sequence Detection System (Applied Biosystems). Patients were assigned to the VKORC1 haplotype group A with the use of five VKORC1 variants, numbered according to the GenBank accession number AY587020 genomic sequence at positions 3673, 5808, 6484, 6853, and 7566, as described previously. 9 All other patients were assigned to a haplotype group termed non-A, which corresponds closely to the VKORC1 haplotype group B, as described by Rieder et al. 9 Haplotypes A and B together account for 96 to 99% of the total haplotypes in white Americans. 9
Primary and Secondary Outcomes
We prespecified four primary outcomes for analysis. We calculated the time to the first INR within the therapeutic range and the time to the first INR of more than 4 from the date that warfarin was started. Both of these outcomes were selected specifically to assess the effect of CYP2C9 genotypes and VKORC1 haplotypes on the effect of warfarin during initiation of anticoagulation.
We selected two additional primary outcomes to assess the effect of CYP2C9 and VKORC1 during a longer interval. The time that the patient's INR was above the therapeutic range relative to the complete time of follow-up was calculated by interpolation; the difference between an INR value and the subsequent value was divided by the number of days between these two measurements to establish an average daily increment or decrement. 29 Interpolated INR values were used to calculate the time that patients spent above their individual INR range, relative to the duration of exposure to warfarin. The INR response over time was determined by comparing the average INR value among genotypes during weeks 1 and 2 and during the period between day 29 and the end of follow-up.
Prespecified secondary outcomes included the average daily warfarin dose and bleeding events. The average warfarin daily dose (in milligrams per day) was determined during weeks 1 and 2 and between day 29 and the end of follow-up. In addition, major and minor bleeding events were counted according to the criteria of the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation study. 30
Statistical Analysis
We assessed linkage disequilibrium for the VKORC1 polymorphisms 3673, 6484, 6853, and 7566 by calculating the square of the correlation coefficient (r 2 ) for each pair of variants with the use of genetic-marker data analysis (PowerMarker). 31 The individual haplotypes of patients were estimated for VKORC1 and used for subsequent analyses. Tests for Hardy-Weinberg equilibrium in the population were performed with the use of Haploview software. 32 Frequencies of CYP2C9 genotypes and VKORC1 haplotypes among racial groups were compared with the use of chi-square tests of independence. The characteristics of the patients were compared in the CYP2C9 genotype groups and the VKORC1 haplotype groups with the use of Student's t-test, the chi-square test, or Fisher's exact test, as appropriate. The primary outcomes of the time to the first INR within the therapeutic range and to the first INR of more than 4 were compared among genotype or haplotype groups with the use of log-rank tests. Cox regression analyses were performed to determine the hazard ratio for achieving a first INR within the therapeutic range or a first INR of more than 4 in the first 4 weeks and during the entire follow-up period, according to genotype or haplotype group. We prospectively selected potentially confounding variables, including age, race, sex, use of amiodarone, target INR, starting warfarin dose, number of INR tests, and indication for anticoagulation, to adjust comparisons among genotypes and haplotypes. The primary outcome of the time above the therapeutic INR range was compared according to genotype or haplotype with the use of a Kruskal-Wallis ranksum test for the overall comparison and the Tukey-Kramer honest-significant-differences test for pairwise comparisons. The primary outcome of INR response to warfarin during various time periods was explored with the use of the Kruskal-Wallis rank-sum test to determine whether there was an effect of genotype or haplotype on the INR. The prespecified secondary outcome of the average dose of warfarin was compared among genotypes and haplotypes with the use of Student's t-test.
Data are presented as means (±SD) or as medians with interquartile ranges, as appropriate. All standard statistical tests were performed with the use of SAS software, version 9.1 (SAS Institute). All P-values are two-sided. No statistical corrections for multiple testing were performed.
R e sult s
Population Characteristics
Of the 325 patients who met the entry criteria, 28 were excluded from the analysis for the following reasons (some patients had more than one reason): 7 patients had no INR readings in the first 10 days after the start of warfarin treatment, 12 patients had fewer than two INR readings, 6 patients had no target INR recorded or the target INR was outside the range of 1.8 to 3.5, 3 patients provided no DNA or the DNA was of poor quality, 3 patients had incomplete baseline data collection, 1 patient did not provide a blood sample, 1 patient did not have a recorded start date for warfarin, and 1 patient was undergoing chemotherapy. These exclusions resulted in a final study population of 297 patients. Table 1 summarizes the characteristics of the patients. The target INR ranged from 1.8 to 3.5 and was 2 to 3 in 69% of the patients. The average initial warfarin dose was 4.8±0.8 mg. There was no significant difference among patients with the various CYP2C9 genotypes and VKORC1 haplotypes with respect to age, sex, underlying diagnosis, target INR, initial warfarin dose, and proportion of patients receiving concomitant drugs that could potentiate or attenuate the effect of warfarin. The mean numbers of INR measurements during the first 28 days and the entire study period were 7.7±3.8 and 12.4±6.4, respectively, and did not differ significantly among patients with CYP2C9 genotypes and VKORC1 haplotypes (P>0.30 for all comparisons). The median follow-up interval was 43 days. Interquartile range 2-42
The promoter and intronic VKORC1 polymorphisms 3673, 6484, 6853, and 7566 were in strong linkage disequilibrium (r 2 ≥0.85). The allelic frequency of haplotype A was 32.6%, including 129 heterozygotes and 32 homozygotes (Table 2) , and was significantly lower among black patients (13.8%) than among white patients (34.3%) (P = 0.006).
The allelic frequencies of CYP2C9*2 and CYP2C9*3 were 12.0% and 4.8%, respectively. CYP2C9*5 was not found in any of the patients. For analysis, CYP2C9 genotypes were considered in three groups: CYP2C9*1/*1 (wild type), CYP2C9*1/*2 and CYP2C9*1/*3 (heterozygotes), and CYP2C9*2/*2, CYP2C9*3/*3, and CYP2C9*2/*3 (homozygotes and compound heterozygotes). The frequency of the CYP2C9 genotype groups varied significantly among racial or ethnic groups (P = 0.005) ( Table 2 ). There was no deviation from the expected proportions of genotypes in the population predicted by the Hardy-Weinberg equilibrium for polymorphisms in VKORC1, CYP2C9*2, and CYP2C9*3. Figure 1 shows the primary outcomes of the times to the first therapeutic INR and to the first INR of more than 4 among various genotypes. The VKORC1 haplotype had a significant effect on the time that was required to reach the first INR within the therapeutic range (P = 0.02) and the time to the first INR of more than 4 (P = 0.003) (Fig. 1A and 1B and Table 3 ). Patients with one or two VKORC1 haplotype A alleles had shorter times to the first INR within the therapeutic range and to an INR of more than 4 than did patients with two haplotype non-A alleles (Table 4) . Concordant with these findings, Cox regression analysis with statistical adjustment for potentially confounding covariates showed that among A/A homozygotes, the rate of achieving a first INR within the therapeutic range (both during the initial 28 days and the entire follow-up period) was higher than that of non-A/non-A homozygotes by a factor of nearly 2.4 (P<0.001 for both comparisons); the rate of reaching an INR of more than 4 was higher by more than a factor of 2.5 during the corresponding periods (P = 0.009 for both comparisons) (Table 4 ). Patients carrying only one A allele were also at higher risk.
Time to First INR in Therapeutic Range and First INR Above 4
In contrast, the CYP2C9 genotype did not significantly affect the time to the first INR within the therapeutic range (Tables 3 and 4 and Fig. 1C) . Carriers of CYP2C9*2 and CYP2C9*3 variant alleles did reach a first INR of more than 4 earlier than did patients with the wild-type allele (P = 0.03) (Fig. 1D) . This finding was reflected in an increased hazard ratio (Table 4) .
Time above the Therapeutic INR Range
The VKORC1 haplotype had a significant effect on the primary outcome of the percentage of time above the therapeutic INR range (P = 0.03). Patients who were homozygous for VKORC1 haplotype A spent significantly more treatment time above their therapeutic INR range than did patients who were homozygous for the non-A haplotype (median percentage, 18.8% vs. 9.1%; P = 0.02). The association between the CYP2C9 genotype and the time above the therapeutic INR range was weaker and not statistically significant (P = 0.09).
INR Response over Time
Genotype differences in INR were more marked early in therapy, probably because the dose of warfarin was titrated according to the INR; therefore, later INR responses reflected this titration (Table 5 ). The primary outcome of the average INR response was significantly affected by the VKORC1 haplotype during the first 2 weeks of treatment (P<0.001 for both week 1 and week 2); this relationship was weaker for the CYP2C9 genotype groups (P = 0.17 for week 1 and P = 0.04 for week 2).
Single-Gene Effects on Warfarin Dose Requirement
The VKORC1 haplotype affected the prespecified secondary outcome of average warfarin dose in weeks 1 and 2 and from day 29 to the end of follow up (P<0.001 for all comparisons) (Table 5 ).
There was a gene-dose effect, with haplotype A associated with a higher INR response requiring lower doses of warfarin. The CYP2C9 genotype was also associated with the warfarin dose, but the effect was less marked during the first 2 weeks of therapy than after the first 28 days (Table 5) .
Bleeding Risk
The risk of bleeding was assessed as a prespecified secondary outcome. There were eight major and five minor bleeding events involving 12 patients (1 patient had two events), as defined by the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation study 30 (Table 3 of INR of 3.7 (range, 1.7 to 12.3). Patients with bleeding events were older (median age, 71 years) than the study population (median age, 61 years). Two patients with bleeding events were homozygous for CYP2C9*2, three were heterozygous (one patient had CYP2C9*1/*2, and two patients had CYP2C9*1/*3), and seven had CYP2C9*1/*1. Three patients were homozygous for VKORC1 haplotype non-A, seven were heterozygous for non-A/A, and two were homozygous for A.
Dis cus sion
This study of patients who were starting warfarin therapy investigated the relationship between VKORC1 haplotypes and CYP2C9 genotypes and the INR responses that are used to adjust doses. The major finding was that genetic variation in VKORC1, but not in CYP2C9, modulates the early response to warfarin. We found that patients carrying VKORC1 haplotype A had significantly higher INR values in the first week than did non-A homozygotes. These differences in response occurred despite empiric dose adjustment of warfarin. In contrast, the CYP2C9 genotype did not significantly affect INR responses during the first week. We also found that the VKORC1 haplotype predicted both the time to the first INR within the therapeutic range and the time to the first INR of more than 4. Among patients who were carrying two A alleles, the rate of reaching these outcomes at given time intervals was approximately twice that of non-A homozygotes; patients with one A allele also showed an increased risk of reaching an INR above 4.
Most recent studies of the role of genetic variants in the response to warfarin enrolled patients receiving stable anticoagulation 13, [15] [16] [17] [18] 33 or those who had undergone 1 to 3 months of warfarin pretreatment. 10, 11, 14 Studies that enrolled patients who were just starting therapy have primarily focused on differences in the warfarin dose. 9,12 Two studies analyzing the first few weeks of warfarin treatment showed that among carriers of the CYP2C9*2 or CYP2C9*3 allele, the proportion of patients with INR values of more than 3 was higher than that of patients who were not carriers. 34, 35 However, in a study in which the prospective dose of warfarin was based on CYP2C9 genotype, carriers of a variant allele had an increased risk of having an INR of more than 4. 36
Our findings contrast with those of a recent study by Millican et al. 37 that examined the use of clinical and genetic variables for predicting the maintenance dose of warfarin in 92 patients. In that study, genotyping for VKORC1 contributed little to the final statistical model; the INR after the third dose of warfarin was the strongest predictor of the maintenance dose. As we have shown, the early INR response is strongly affected by the VKORC1 haplotype. Thus, as shown by Millican et al., the contribution of VKORC1 was captured in the INR after three doses of warfarin.
An increase in the anticoagulant response over time (as indicated by an INR above the therapeutic range) is associated with an increased risk of bleeding. 3 Therefore, in addition to the time to the first INR of more than 4, the amount of time spent above the therapeutic INR range is informative. In our study, the VKORC1 haplotype affected the time that patients spent above the therapeutic INR range, whereas the CYP2C9 genotype had a marginal effect. However, both the VKORC1 haplotype and the CYP2C9 genotype had a significant effect on the warfarin dose after the first 2 weeks. Our results confirm the relationship between the CYP2C9 genotype and the response to warfarin that has been observed by others, 6, 36, 38 but they also indicate that early in the course of anticoagulation the effect of the VKORC1 haplotype is greater than that of the CYP2C9 genotype, and the presence of a VKORC1 A allele is associated with an accelerated and greater sensitivity to warfarin. Serious bleeding events were not significantly affected by the presence of the VKORC1 haplotype or CYP2C9 genotype. However, our study focused on changes in the INR and the warfarin dose during the first few weeks of therapy and not with therapy of longer duration, so the number of events was small.
In conclusion, during the initial phase of anticoagulation, genetic variants of VKORC1 are a major determinant of variability in sensitivity to war- No potential conflict of interest relevant to this article was reported.
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